



Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer

Cambridge, UK, 14 June 2017 – Crescendo Biologics Ltd (Crescendo), a company developing highly potent and differentiated Humabody® therapeutics, today announced that Edward J. “Tad” Stewart has joined the company as Chief Business Officer.

Dr. Peter Pack, CEO of Crescendo Biologics commented:

“Crescendo’s platform is delivering a robust pipeline of intrinsically differentiated, multi-functional therapeutics in the oncology space. As we continue our growth, we look forward to exploring new partnership opportunities that can advance our pipeline and leverage the capabilities of our transgenic platform. A strong and experienced team is key to reaching our ambitions and Tad brings broad experience in business and corporate development as well as organizational growth, making him a great addition to our leadership team as we accelerate the evolution of Crescendo.”

Tad Stewart, the new CBO, added:

“Crescendo is developing a very exciting and highly differentiated pipeline of therapeutics. I look forward to joining the team and contributing my experience to advance those products, achieve our corporate goals and realize the full potential of the Humabody® platform.”

Tad brings over twenty years of experience working in the biotechnology field. He joins Crescendo from Merrimack Pharmaceuticals, Inc. where he served in several executive roles, including leading the commercial business unit and the business development function. Tad was one of the first employees of Merrimack and his experience spans the growth of the company from a pre-clinical organization to a commercial enterprise, comprising of the successful launch of a marketed oncology product and execution of several transactions that supported the long-term growth of the company. Prior to Merrimack, Tad worked across the biotech, pharmaceutical and medical device industries as a consultant. Tad holds an MBA from the Johnson School at Cornell University and a BS in Biology from Bates College.

Ends

For more information, please contact:

Crescendo Biologics
Dr Peter Pack, CEO

Tel:44 (0)1223 497140
info@crescendobiologics.com

Instinctif Partners
Dr Christelle Kerouedan / Melanie Toyne-Sewell

Tel:44 (0)20 7457 2020
crescendo@instinctif.com



Notes to Editors

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody[®] therapeutics in oncology. It is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships in both multi-functional immuno-oncology modulators and Humabody[®] Drug Conjugates (HDCs), the next generation of ADCs.

The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V_H domain building blocks (Humabody[®] V_H) comprising the full structural diversity of the human V_H repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com.

About Humabody[®] Therapeutics

Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human V_H domain building blocks (Humabody[®] V_H) isolated from heavy chain-only antibodies produced using Crescendo's proprietary transgenic mouse.

Compared with monoclonal antibodies, Humabodies[®] offer a unique combination of potential benefits resulting from their broad structural diversity, small size, high yield and robust biophysical properties. These attributes allow Crescendo to configure an almost limitless range of multi-specific and multi-functional Humabody[®] formats in a rapid timeframe.

Crescendo is developing a pipeline of novel, Humabody[®]-based therapeutics in oncology. Next-generation multi-specific Humabody[®] IO modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response as well as specific targeting of IO modulators into the tumor-microenvironment, enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment. Humabody[®] Drug Conjugates (HDCs) demonstrate a superior therapeutic index to standard ADCs.

For more information, please visit the website: www.crescendobiologics.com/humabody.